Du Xue, Che Yuanyuan, Yuan Yi, Zhang Qin, Zou Xueyang, Huang Jing
Department of Clinical Laboratory, The First Hospital of Jilin University, 1 Xinmin Street, Changchun, 130021, Jilin, P.R. China.
Department of Rheumatology and Immunology, The First Hospital of Jilin University, 1 Xinmin Street, Changchun, 130021, Jilin, P.R. China.
Sci Rep. 2025 Mar 20;15(1):9588. doi: 10.1038/s41598-025-93771-2.
We evaluated the clinical and laboratory features of decreased serum calcium (albumin corrected or uncorrected) compared to non-hypocalcemia in SLE patients. Exploring the value of serum calcium in assessing the activity and prognosis of SLE disease. Retrospective analysis and comparison of clinical and laboratory data obtained during the treatment period of SLE patients from 2018 to 2023. Both quantity and titer of serum anti-dsDNA antibodiesin SLE patients with hypocalcemia were significantly increased, and peripheral leucocytes, platelets, complement C3 or C4 reduced, while urinary cast and 24 h urine protein elevated. SLEDAI-2 K, BILAG and PGA have confirmed that SLE patients with decreased serum calcium had stronger disease activity, even without positive titers of anti-dsDNA antibodies. Multivariate analysis showed that the decreased serum calcium (OR, 0.31; 95% CI, 0.11, 0.89; P, 0.030) and positive anti-dsDNA antibodies (OR, 0.13; 95% CI, 0.04, 0.44; P, 0.001) are risk factors for increased disease activity in SLE. The Cox model showed that for newly diagnosed SLE and hypocalcemia patients, the stability time of GCs treatment may be prolonged. With the recovery of total calcium, disease activity and laboratory indicators could improve.SLE patients with decreased serum calcium have stronger disease activity and require longer treatment time for remission. Serum calcium levels may assist in assessing disease activity and predicting prognosis.
我们评估了系统性红斑狼疮（SLE）患者血清钙降低（校正或未校正白蛋白）与非低钙血症相比的临床和实验室特征。探讨血清钙在评估SLE疾病活动度和预后中的价值。对2018年至2023年SLE患者治疗期间获得的临床和实验室数据进行回顾性分析和比较。低钙血症的SLE患者血清抗双链DNA抗体的数量和滴度均显著增加，外周白细胞、血小板、补体C3或C4降低，而尿沉渣和24小时尿蛋白升高。SLEDAI-2K、BILAG和PGA已证实，血清钙降低的SLE患者疾病活动度更强，即使抗双链DNA抗体滴度未呈阳性。多因素分析显示，血清钙降低（OR，0.31；95%CI，0.11，0.89；P，0.030）和抗双链DNA抗体阳性（OR，0.13；95%CI，0.04，0.44；P，0.001）是SLE疾病活动度增加的危险因素。Cox模型显示，对于新诊断的SLE和低钙血症患者，糖皮质激素（GCs）治疗的稳定时间可能会延长。随着总钙的恢复，疾病活动度和实验室指标可能会改善。血清钙降低的SLE患者疾病活动度更强，缓解所需的治疗时间更长。血清钙水平可能有助于评估疾病活动度和预测预后。
